SCHEMBL1093649

SCHEMBL1093649

N#Cc1cc(S(=O)(=O)N(C(=O)O)c2cscn2)ccc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.38
SCN5A Q14524 2/20 0.37
SCN1A P35498 1/20 0.37
SCN8A Q9UQD0 1/20 0.37
HSP90AA1 P07900 2/20 0.37
HSP90AB1 P08238 2/20 0.37
GRM4 Q14833 1/20 0.36
ACLY P53396 2/20 0.36
SCN9A Q15858 3/20 0.35
AKR1C3 P42330 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
SLC22A12 Q96S37 2/20 0.34
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
AR P10275 1/20 0.32
APAF1 O14727 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
BLM P54132 1/20 0.32
WRN Q14191 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1094339 0.86 SCN8A (0.43) PTGDR2SCN5ASCN1ASCN8AHSP90AA1
SCHEMBL19613839 0.83 FLT1 (0.42) PTGDR2SCN5ASCN1ASCN8AGRM4
SCHEMBL19614057 0.81 TRPM8 (0.42) SCN5ASCN1ASCN8AGRM4TRPM8
SCHEMBL20237840 0.80 SCN1A (0.66) SCN5ASCN1ASCN8ASCN9AAPAF1
SCHEMBL20237835 0.80 SCN1A (0.66) SCN5ASCN1ASCN8ASCN9AAPAF1
SCHEMBL1094795 0.80 SLC22A12 (0.51) SCN9ASLC22A12
SCHEMBL1094341 0.78 PTGDR2 (0.35) PTGDR2SCN5AHSP90AA1HSP90AB1GRM4
SCHEMBL19617873 0.74 SCN8A (0.37) SCN5ASCN1ASCN8AGRM4
SCHEMBL19613825 0.74 FLT1 (0.34) SCN5ASCN1ASCN8ATRPM8MAPT
SCHEMBL19617228 0.73 SCN8A (0.38) SCN5ASCN1ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 US disclosed
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2021-06-10 US disclosed
EP-3551626-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2019-10-16 EP disclosed
US-20180162868-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2018-06-14 US disclosed
WO-2018106284-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2018-06-14 WO disclosed
EP-2385938-B1 SULFONAMIDE DERIVATIVES PFIZER LTD (GB) 2015-03-04 EP disclosed
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
WO-2014170793-A1 SULFONAMIDES FOR THE TREATMENT OF GOUT PFIZER LIMITED (GB) 2014-10-23 WO disclosed
US-20140315933-A1 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2014-10-23 US disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-8541588-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2013-09-24 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
EP-2385938-A1 SULFONAMIDE DERIVATIVES Pfizer Limited (GB) 2011-11-16 EP disclosed
US-8040476-B2 Display device and method of producing the same MITSUBISHI ELECTRIC CORPORATION (JP) 2011-10-18 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed
WO-2010079443-A1 SULFONAMIDE DERIVATIVES PFIZER LIMITED (GB) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315933-A1 CHEMICAL COMPOUNDS SULT2A1, SULT1A1, SULT1E1 PTGDR2 3000/4885SCN5A 686/4885SCN1A 312/4885
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 PTGDR2 619/4885SCN5A 19/4885SCN1A 23/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 PTGDR2 619/4885SCN5A 19/4885SCN1A 23/4885
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents KCND2, SCN1A, CACNA1D PTGDR2 987/4885SCN5A 42/4885SCN1A 2/4885
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B PTGDR2 1645/4885SCN5A 10/4885SCN1A 1/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 PTGDR2 619/4885SCN5A 19/4885SCN1A 23/4885
US-20180162868-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B PTGDR2 1645/4885SCN5A 10/4885SCN1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.